ライフサイエンスコーパス: intravascular ultrasound

1 evation myocardial infarction (NSTEMI) using intravascular ultrasound.

2 py with FFR, near-infrared spectroscopy, and intravascular ultrasound.

3 oherence tomography and 0.17+/-0.26 mm(2) on intravascular ultrasound.

4 maging is hampered by the invasive nature of intravascular ultrasound.

5 served in 16 of 42 patients (38%) undergoing intravascular ultrasound.

6 atheroma progression was evaluated by serial intravascular ultrasound.

7 dent predictors for future cardiac events by intravascular ultrasound.

8 me (PAV) from baseline to 1 year measured by intravascular ultrasound.

9 allograft vascular disease (CAV) assessed by intravascular ultrasound.

10 red to reduce atheroma volume as measured by intravascular ultrasound.

11 d severe coronary arteriopathy documented by intravascular ultrasound.

12 ared with catheter angiographic findings and intravascular ultrasound.

13 , allograft vasculopathy is best detected by intravascular ultrasound.

14 l plaque volume was measured by quantitative intravascular ultrasound.

15 ive biopsies developed intimal thickening by intravascular ultrasound.

16 prit lesions identified on virtual-histology intravascular ultrasound.

17 y endovascular treatment using tools such as intravascular ultrasound.

18 nd plaque index (PI) per year using coronary intravascular ultrasound.

19 tients undergoing 3-vessel virtual-histology intravascular ultrasound.

20 CAV was investigated using intravascular ultrasound.

21 by consecutive volumetric three-dimensional intravascular ultrasound.

22 15 mm vs 1.46 mm, p<0.0001) and quantitative intravascular ultrasound (2.85 mm(2)vs 3.60 mm(2), p<0.0

23 (mean 49 years old) using three-dimensional intravascular ultrasound (3-D IVUS) examination of the l

24 grade IV coronary allograft vasculopathy on intravascular ultrasound, 3 of whom had angiographic dis

25 formation were studied with angiography and intravascular ultrasound 6 months after the index PCI.

26 e in first-year maximal intimal thickness by intravascular ultrasound, a recognized surrogate for lon

27 Serial volumetric intravascular ultrasound analyses (poststent and follow-

28 Intravascular ultrasound analysis at 9 months and final

29 nsplant recipients had baseline and one-year intravascular ultrasound analysis done to assess the pro

30 Serial 3-dimensional intravascular ultrasound analysis in the left anterior d

31 At 3 months, intravascular ultrasound analysis revealed that lumen cr

32 Serial (pre-, post- and follow-up) intravascular ultrasound analysis was performed in 46 na

33 Methods and Results- Volumetric intravascular ultrasound analysis was performed in 70 IS

34 <=0.85, and 20 vessels >0.85 high definition intravascular ultrasound analysis was performed.

35 Intravascular ultrasound and cardiac magnetic resonance

36 Using serial studies with intravascular ultrasound and Doppler flow-wire measureme

37 Intravascular ultrasound and histology showed no effect

38 Intravascular imaging-intravascular ultrasound and more recently optical coher

39 Recent findings utilizing intravascular ultrasound and optical coherence tomograph

40 w focuses on basic image interpretation with intravascular ultrasound and optical coherence tomograph

41 in could regress coronary atherosclerosis by intravascular ultrasound and quantitative coronary angio

42 e vessel wall are apparent on angiography or intravascular ultrasound and that it has a prognostic va

43 ated in vivo based on virtual histology (VH) intravascular ultrasound and whether PSS varied accordin

44 ged by means of invasive techniques, such as intravascular ultrasound (and derived techniques), optic

45 intravascular ultrasound (virtual histology intravascular ultrasound) and computational fluid dynami

46 ural infarction using angiographic analysis, intravascular ultrasound, and delayed-enhancement magnet

47 mittee, and all imaging including venograms, intravascular ultrasound, and Doppler examinations were

48 on, including fluoroscopy, echocardiography, intravascular ultrasound, and electron beam computed tom

49 allograft vasculopathy (CAV) assessed by 3D intravascular ultrasound, and incidence of cardiac adver

50 Patients underwent serial coronary intravascular ultrasound, and interstitial myocardial fi

51 9-17 years) underwent coronary angiography, intravascular ultrasound, and MRI.

52 , such as quantitative coronary angiography, intravascular ultrasound, and optical coherence tomograp

53 ility have been described by CT angiography, intravascular ultrasound, and optical coherence tomograp

54 eds conventional magnetic resonance imaging, intravascular ultrasound, and optical coherence tomograp

55 rvation systems by quantitative angiography, intravascular ultrasound, and optical coherence tomograp

56 , such as quantitative coronary angiography, intravascular ultrasound, and optical coherence tomograp

57 erence in luminal dimension was confirmed by intravascular ultrasound assessment of the minimum lumen

58 Intravascular ultrasound assessments showed a preservati

59 All patients underwent intravascular ultrasound at 1 month and 1 year after tra

60 y angiography and 90 grafts were examined by intravascular ultrasound at 1 year after CABG.

61 Follow-up included coronary angiography and intravascular ultrasound at 4 months and clinical assess

62 subgroup of patients (n=56) underwent serial intravascular ultrasound at baseline and 9 months indica

63 Intravascular ultrasound at one year demonstrated rapid

64 Intravascular ultrasound-based 3-dimensional reconstruct

65 Results- Intravascular ultrasound-based, geometrically correct 3-

66 laque volume in ACS patients, as assessed by intravascular ultrasound, but no clinical trials assessi

67 cular ultrasound (IB-IVUS), and conventional intravascular ultrasound (C-IVUS) for tissue characteriz

68 agnosis of ISA, initially only possible with intravascular ultrasound, can currently be performed wit

69 ent minus lumen) areas and source-to-target (intravascular ultrasound catheter to external elastic me

70 thod of transthoracic echocardiography (with intravascular ultrasound catheters) at baseline and on d

71 The coprimary end point of first-year intravascular ultrasound change demonstrated no differen

72 patients who had undergone virtual histology intravascular ultrasound characterization of coronary pl

73 nce assessed by quantitative angiography and intravascular ultrasound; composite clinical endpoints b

74 dicts a suboptimal result based on validated intravascular ultrasound criteria; however, an FFR >/=0.

75 from baseline of percent atheroma volume on intravascular ultrasound, CRP-modulating effects, or MAC

76 ubstudies, 103 patients (54 BMS, 49 PES) had intravascular ultrasound data >/=10 mm distal to the ste

77 Intravascular ultrasound data at the sites of PP were co

78 raft plaque was divided on virtual histology intravascular ultrasound-derived "inflammatory" (VHD-IP)

79 dy to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burde

80 dy to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burde

81 giographic disease (n=23) and NSTEMI (n=24), intravascular ultrasound-derived measures (percent ather

82 ), changes in plaque area, virtual histology intravascular ultrasound-derived plaque composition, and

83 Intravascular ultrasound detects stent edge dissections

84 NIRS-intravascular ultrasound device-related events were seen

85 theter thrombolysis regimen, the addition of intravascular ultrasound did not facilitate thrombus res

86 The Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus

87 hanges in lipoprotein levels and the primary intravascular ultrasound end point, change in percent at

88 irty-two consecutive HT recipients underwent intravascular ultrasound evaluation at month 1 and year

89 ith coronary artery disease underwent serial intravascular ultrasound examination in 7 clinical trial

90 cipients between 1993 and 1995 who underwent intravascular ultrasound examination of the coronary art

91 d and received study drug; 502 had evaluable intravascular ultrasound examinations at baseline and af

92 tients with coronary bifurcation lesion, 120 intravascular ultrasound examinations of the MV were per

93 After serial intravascular ultrasound examinations, only small remnan

94 y was performed regardless of performance of intravascular ultrasound examinations.

95 ared serial (postintervention and follow-up) intravascular ultrasound findings in 66 patients with na

96 scribe near-infrared spectroscopy (NIRS) and intravascular ultrasound findings in pre-existing stents

97 Intravascular ultrasound findings suggesting thrombus we

98 At the site of LRP, intravascular ultrasound found no neointimal tissue in 3

99 nt coronary angiography followed by coronary intravascular ultrasound, fractional flow reserve, and i

100 A total of 4429 VH intravascular ultrasound frames from 53 patients were an

101 eration DES (HR=1.75, P=0.02), no procedural intravascular ultrasound guidance (HR=1.75, P=0.04), and

102 The frequency of ST may be reduced with intravascular ultrasound -guided stenting, assiduous adh

103 Intravascular ultrasound-guided stent overexpansion (fin

104 ave not systematically evaluated the role of intravascular ultrasound-guided stenting and high platel

105 Intravascular ultrasound-guided stenting has been shown

106 ified 989 consecutive patients who underwent intravascular ultrasound-guided stenting of 1,015 corona

107 SF defined by catheter angiography or intravascular ultrasound has been implicated in ISR.

108 Intravascular ultrasound has been used to gain important

109 ontemporary imaging technology, particularly intravascular ultrasound, has allowed the study of arter

110 In vivo studies with intravascular ultrasound have shown that complex plaque

111 nce tomography (OCT), integrated backscatter intravascular ultrasound (IB-IVUS), and conventional int

112 Intravascular ultrasound identified intramural hematomas

113 he left anterior descending coronary artery; intravascular ultrasound images and Doppler velocities w

114 Coronary angiography and intravascular ultrasound images were analyzed.

115 In each segment, intravascular ultrasound images were digitized at 1-mm i

116 Intravascular ultrasound images were digitized every 1 m

117 NIRS-intravascular ultrasound imaging adds to the armamentari

118 e relationship between LRPs detected by NIRS-intravascular ultrasound imaging at unstented sites and

119 Near-infrared spectroscopy (NIRS) intravascular ultrasound imaging can detect lipid-rich p

120 Intravascular ultrasound imaging is the most sensitive t

121 Baseline intravascular ultrasound imaging was performed 0.9 +/- 0

122 Repeat intravascular ultrasound imaging was performed after con

123 scanning of non-culprit segments using NIRS-intravascular ultrasound imaging.

124 nt serial evaluation of atheroma burden with intravascular ultrasound imaging.

125 ed in 7 clinical trials that employed serial intravascular ultrasound imaging.

126 t coronary artery disease (CAD) using serial intravascular ultrasound imaging.

127 This is the first study of POT guided by intravascular ultrasound in patients with coronary bifur

128 s with symptomatic carotid disease, and with intravascular ultrasound in patients with stable angina.

129 Intima-media thickness was assessed by intravascular ultrasound in the coronary arteries at wee

130 Intravascular ultrasound is an accurate method to assess

131 Intravascular ultrasound is invasive and costly.

132 Intravascular ultrasound is more sensitive than coronary

133 ases (SES: 72; BMS: 50) with complete serial intravascular ultrasound (IVUS) (baseline and 8-month fo

134 Arteries were imaged with intravascular ultrasound (IVUS) 5 and 10 min after ELIP

135 Serial volumetric intravascular ultrasound (IVUS) analysis was performed i

136 Intravascular ultrasound (IVUS) and cardiac MRI (CMR) we

137 Intravascular ultrasound (IVUS) and fractional flow rese

138 general, it has a good correlation with both intravascular ultrasound (IVUS) and histopathology for d

139 tent of coronary atherosclerosis assessed by intravascular ultrasound (IVUS) and its rate of progress

140 sel imaging was performed with a combination intravascular ultrasound (IVUS) and near-infrared spectr

141 hereby assessed whether integrating EIS with intravascular ultrasound (IVUS) and shear stress (ISS) p

142 Concomitant OCT and intravascular ultrasound (IVUS) area measurements were p

143 rwent simultaneous endomyocardial biopsy and intravascular ultrasound (IVUS) at one year of transplan

144 We assessed the pre- and post-PCI intravascular ultrasound (IVUS) characteristics of subac

145 We hypothesized that intravascular ultrasound (IVUS) could accurately visuali

146 sought to assess the validity of first-year intravascular ultrasound (IVUS) data as a surrogate mark

147 Serial intravascular ultrasound (IVUS) data from the Reversal o

148 Spectral analysis of backscattered intravascular ultrasound (IVUS) data has potential for r

149 In vivo intravascular ultrasound (IVUS) data were acquired from

150 nderwent coronary angiography and volumetric intravascular ultrasound (IVUS) evaluation of the left a

151 Patients underwent intravascular ultrasound (IVUS) evaluation of the target

152 s designed to examine the impact of repeated intravascular ultrasound (IVUS) examinations on transpla

153 thickness (CMIT) and plaque volume (CPV) by intravascular ultrasound (IVUS) examinations.

154 We report intravascular ultrasound (IVUS) findings after crush-ste

155 era of drug-eluting stents, it is unknown if intravascular ultrasound (IVUS) guidance for percutaneou

156 Intravascular ultrasound (IVUS) guidance has been shown

157 to modest-sized studies suggest a benefit of intravascular ultrasound (IVUS) guidance in noncomplex l

158 l studies have indicated better outcome with intravascular ultrasound (IVUS) guidance when performing

159 Intravascular ultrasound (IVUS) has become an indispensa

160 Intravascular ultrasound (IVUS) has played an integral r

161 Intravascular ultrasound (IVUS) has the ability to detec

162 neously obtained endomyocardial biopsies and intravascular ultrasound (IVUS) images of coronary arter

163 Optical coherence tomography and intravascular ultrasound (IVUS) images of these sites we

164 Participants underwent coronary intravascular ultrasound (IVUS) imaging and were randomi

165 ultaneous optical coherence tomography (OCT)-intravascular ultrasound (IVUS) imaging at 72 frames per

166 scending artery and compared with volumetric intravascular ultrasound (IVUS) imaging.

167 Intravascular ultrasound (IVUS) is being used to assess

168 It can only be detected if intravascular ultrasound (IVUS) is performed at follow-u

169 tent malapposition (LSM) is only detected if intravascular ultrasound (IVUS) is performed at implanta

170 Although intravascular ultrasound (IVUS) is widely used to detect

171 T (0.75-mm collimation, 420-ms rotation) and intravascular ultrasound (IVUS) of one coronary artery w

172 who underwent stenting under the guidance of intravascular ultrasound (IVUS) or conventional angiogra

173 High-frequency intravascular ultrasound (IVUS) revealed atherosclerotic

174 Previous intravascular ultrasound (IVUS) studies have demonstrate

175 Coronary angiography and intravascular ultrasound (IVUS) studies were performed a

176 Serial 3-dimensional intravascular ultrasound (IVUS) studies were performed w

177 The 274 patients who completed the intravascular ultrasound (IVUS) substudy of the CAMELOT

178 mine the optimal minimum lumen area (MLA) by intravascular ultrasound (IVUS) that correlates with fra

179 We used intravascular ultrasound (IVUS) to assess 78 coronary ar

180 We used serial intravascular ultrasound (IVUS) to assess disease progre

181 The goal of this study was to use intravascular ultrasound (IVUS) to compare octogenarians

182 volumetric (post-irradiation and follow-up) intravascular ultrasound (IVUS) to compare the effective

183 The current study analyzed intravascular ultrasound (IVUS) to define the changes th

184 We used diagnostic and preintervention intravascular ultrasound (IVUS) to determine the inciden

185 We used intravascular ultrasound (IVUS) to evaluate recurrence a

186 This study used serial volumetric intravascular ultrasound (IVUS) to evaluate the effect o

187 m of this study was to use serial volumetric intravascular ultrasound (IVUS) to evaluate the effects

188 The aim of this study was to use serial intravascular ultrasound (IVUS) to evaluate the long-ter

189 We used serial intravascular ultrasound (IVUS) to study patients with l

190 Prior intravascular ultrasound (IVUS) trials have demonstrated

191 Intravascular ultrasound (IVUS) was used to evaluate 38

192 Patients undergoing TEVAR with intravascular ultrasound (IVUS) were analysed and IFM wa

193 tics, quantitative coronary angiography, and intravascular ultrasound (IVUS) were evaluated in subjec

194 s the first intravascular catheter combining intravascular ultrasound (IVUS) with multispectral fluor

195 enal translesional pressure gradients (TPG), intravascular ultrasound (IVUS), and angiographic parame

196 Six-month angiographic, intravascular ultrasound (IVUS), and clinical follow-up

197 atients (B2) underwent coronary angiography, intravascular ultrasound (IVUS), and optical coherence t

198 to compare color-flow duplex imaging (CFDI), intravascular ultrasound (IVUS), and renal arteriography

199 Intravascular ultrasound (IVUS)-attenuated plaque is cha

200 Are progressive changes in intravascular ultrasound (IVUS)-derived indexes of plaqu

201 Intravascular ultrasound (IVUS)-derived lumen, outer ste

202 was to investigate the relationship between intravascular ultrasound (IVUS)-derived measures of athe

203 his study was to evaluate the efficacy of an intravascular ultrasound (IVUS)-guided strategy for pati

204 g coronary three-dimensional (3D) volumetric intravascular ultrasound (IVUS).

205 etes mellitus using 3-dimensional volumetric intravascular ultrasound (IVUS).

206 ivo, and results were compared with those of intravascular ultrasound (IVUS).

207 ut not in SVGs have been well described with intravascular ultrasound (IVUS).

208 ents measured atherosclerosis progression by intravascular ultrasound (IVUS).

209 ment of coronary flow reserve (CFR), and (3) intravascular ultrasound (IVUS).

210 cebo on coronary atheroma burden measured by intravascular ultrasound (IVUS).

211 hic correlates of plaque rupture detected by intravascular ultrasound (IVUS).

212 ses of qDES compared with BMS as assessed by intravascular ultrasound (IVUS).

213 l LAD plaque volume was determined by use of intravascular ultrasound (IVUS).

214 ssed in 108 native coronary lesions by using intravascular ultrasound (IVUS).

215 ith decreased coronary plaque progression by intravascular ultrasound (IVUS).

216 al coronary angiography (CCAG) alone or with intravascular ultrasound (IVUS).

217 l (postirradiation and follow-up) volumetric intravascular ultrasound (IVUS): 1) to evaluate the actu

218 s include fractional flow reserve; grayscale intravascular ultrasound (IVUS); IVUS radiofrequency tis

219 dy comparing SES and BMS, serial qualitative intravascular ultrasound (IVUS; at stent implantation an

220 tissue at the site of LRP detected by NIRS, intravascular ultrasound may provide some insight into t

221 ed quantitative angiography and morphometric intravascular ultrasound measurements pre and post proce

222 tin Versus Atorvastatin (SATURN) used serial intravascular ultrasound measures of coronary atheroma v

223 Paired intravascular ultrasound measures were available at base

224 LGE scores correlate well with traditional intravascular ultrasound measures.

225 In atherosclerosis, 2D NIRF, intravascular ultrasound-NIRF fusion, microscopy, and im

226 We investigated the role of POT guided by intravascular ultrasound on the main vessel (MV) stent e

227 change in total plaque volume at 90 days by intravascular ultrasound, on average decreased by 4.81%

228 ral care were examined, including the use of intravascular ultrasound, optical coherence tomography,

229 and a subgroup of patients was scheduled for intravascular ultrasound, optical coherence tomography,

230 hod among quantitative coronary angiography, intravascular ultrasound, optical coherence tomography,

231 re available (eg, fractional flow reserve or intravascular ultrasound) or being validated (eg, instan

232 ive measures of restenosis (angiographic and intravascular ultrasound) or its clinical sequelae.

233 clerosis was evaluated by B-mode ultrasound, intravascular ultrasound, or angiography.

234 compared with baseline (0.54+/-1.09 mm(2) on intravascular ultrasound, P=0.003 and 0.77+/-1.33 m(2) o

235 imus-eluting stent groups, respectively, and intravascular ultrasound percent neointimal hyperplasia

236 CAV was diagnosed through intravascular ultrasound performed 1 month and 1 year af

237 Intravascular ultrasound plaque rupture strongly correla

238 nd points, such as quantitative angiography, intravascular ultrasound, plasma biomarkers, and functio

239 We investigated 3D intravascular ultrasound (postprocedure and 6 to 9 month

240 Intravascular ultrasound provided coregistered anatomica

241 Atheroma volume was determined in serial intravascular ultrasound pullbacks in matched arterial s

242 gnificantly correlated with plaque volume by intravascular ultrasound (r=0.69; P<0.0001) but not with

243 (Fractional Flow Reserve and Intravascular Ultrasound Relationship Study [FIRST]; NCT

244 FIRST (Fractional Flow Reserve and Intravascular Ultrasound Relationship Study) aimed to de

245 Although angiographic and intravascular ultrasound results at 8 months demonstrate

246 patients with a post procedural FFR <=0.85, intravascular ultrasound revealed focal signs of luminal

247 For each virtual histology intravascular ultrasound segment (n=2249), changes in pl

248 tive randomized trials using serial coronary intravascular ultrasound, serial changes in coronary per

249 Intravascular ultrasound showed a significantly greater

250 Intravascular ultrasound showed atheroma volume regressi

251 Intravascular ultrasound showed that early failure lesio

252 Intravascular ultrasound shows significant reference seg

253 Intravascular ultrasound studies have demonstrated that

254 these patients subsequently underwent two 3D intravascular ultrasound studies in 2004 to 2006 12 mont

255 one orthotopic heart transplantation, serial intravascular ultrasound studies of the proximal left an

256 Three-dimensional intravascular ultrasound studies were performed at basel

257 Three-dimensional intravascular ultrasound studies were performed at basel

258 S or stable angina, consistent with previous intravascular ultrasound studies.

259 n, and time from transplantation to baseline intravascular ultrasound study were not different (P>0.2

260 iren Quantitative Atherosclerosis Regression Intravascular Ultrasound Study) comparing aliskiren with

261 stents (BMS) on distal vessels in the serial intravascular ultrasound substudies of TAXUS IV, V, and

262 In their intravascular ultrasound substudies, 103 patients (54 BM

263 The intravascular ultrasound substudy enrolled 241 patients

264 METHODS AND A formal intravascular ultrasound substudy enrolled 464 patients

265 e associated with more high-risk features on intravascular ultrasound than those without uptake: posi

266 patients (2433 lesions) were evaluated with intravascular ultrasound to characterize the morphologic

267 We used intravascular ultrasound to determine the incidence, mor

268 creased the positive predictive value for VH intravascular ultrasound to identify clinical presentati

269 SS improved the ability of virtual-histology intravascular ultrasound to predict MACE in plaques with

270 Virtual-histology intravascular ultrasound (VH-IVUS) and optical coherence

271 Recent studies show that virtual histology intravascular ultrasound (VH-IVUS) can identify plaques

272 therosclerotic plaque with virtual histology intravascular ultrasound (VH-IVUS) imaging to assess the

273 vivo CT coregistered with virtual histology intravascular ultrasound (VH-IVUS) in 108 plaques from 5

274 We used virtual histology intravascular ultrasound (VH-IVUS) to investigate the na

275 nderwent baseline and 6-month radiofrequency intravascular ultrasound (virtual histology intravascula

276 Mean neointimal area by intravascular ultrasound was higher in PF-PES than in PB

277 n lumen size by quantitative angiography and intravascular ultrasound was observed in nonballoon dene

278 Intravascular ultrasound was performed after stent deplo

279 Intravascular ultrasound was performed at baseline and f

280 In a subset of these patients (n=1107), intravascular ultrasound was performed at follow-up.

281 Intravascular ultrasound was performed during angiograph

282 Six-month intravascular ultrasound was performed in 20% of the pat

283 Intravascular ultrasound was performed in 24 lesions wit

284 AND Combined near-infrared spectroscopy and intravascular ultrasound was performed in 57 vessels in

285 serial (baseline and 1-year post-transplant) intravascular ultrasound was performed in the first 50 m

286 s, 3-vessel gray-scale and virtual histology intravascular ultrasound was performed in the proximal-m

287 Intravascular ultrasound was performed on 121 patients w

288 Intravascular ultrasound was performed within 2 weeks fo

289 raft vasculopathy (CAV) assessed by coronary intravascular ultrasound was present in 53% (19/36) and

290 PSS derived from virtual-histology intravascular ultrasound was subsequently estimated in n

291 by NIRS in a cohort of pre-existing stents, intravascular ultrasound was used to determine the prese

292 Intravascular ultrasound was used to measure progression

293 ar profiling, using coronary angiography and intravascular ultrasound, was used to reconstruct each a

294 Coronary angiography and three-dimensional intravascular ultrasound were performed at baseline and

295 ne and 6-12 months) coronary angiography and intravascular ultrasound were performed in 2931 lesions

296 uation, serial quantitative angiography, and intravascular ultrasound were performed periprocedurally

297 Changes in atheroma burden monitored by intravascular ultrasound were studied in 3,437 patients

298 mography and near-infrared spectroscopy with intravascular ultrasound were used to characterize NA in

299 erity of GVD was determined every 3 weeks by intravascular ultrasound, which quantified intimal area

300 eserve, endothelial function assessment, and intravascular ultrasound with volumetric analysis were p